jpi-547
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2017 (NCT04335604)
Timeline
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
- Poly [ADP-ribose] polymerase 10INHIBITOR
PARP10 inhibitor
- Poly [ADP-ribose] polymerase 2INHIBITOR
PARP2 inhibitor
- Tankyrase-1INHIBITOR
TNKS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(N2CCN(Cc3ccc4c5c(c(=O)[nH]c4c3)CCCN5)CC2)nc1- Mol. weight
- 400.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095245 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06502743 | Phase 2 | Aug 31, 2024 | Merck, Onconic Therapeutics Inc., Yonsei University |
| NCT05475184 | Phase 2 | Aug 1, 2022 | Onconic Therapeutics Inc. |
| NCT05257993 | Phase 1 | Mar 31, 2022 | Onconic Therapeutics Inc. |
| NCT04335604 | Phase 1 | Dec 6, 2017 | Jeil Pharmaceutical Co., Ltd., National OncoVenture |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Onconic Therapeutics Inc. | For profit | 3 | 2 | 2 | 2022 |
| Jeil Pharmaceutical Co., Ltd. | For profit | 1 | 0 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| National OncoVenture | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1